MX2010002101A - Formulaciones de liposomas de compuestos de acido boronico. - Google Patents

Formulaciones de liposomas de compuestos de acido boronico.

Info

Publication number
MX2010002101A
MX2010002101A MX2010002101A MX2010002101A MX2010002101A MX 2010002101 A MX2010002101 A MX 2010002101A MX 2010002101 A MX2010002101 A MX 2010002101A MX 2010002101 A MX2010002101 A MX 2010002101A MX 2010002101 A MX2010002101 A MX 2010002101A
Authority
MX
Mexico
Prior art keywords
boronic acid
liposomes
compound
acid compounds
liposome formulations
Prior art date
Application number
MX2010002101A
Other languages
English (en)
Inventor
Anthony Huang
Yuanpeng Zhang
Bing Luo
Jinkang Wang
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of MX2010002101A publication Critical patent/MX2010002101A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
    • A61K41/0095—Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe una composición de liposoma que comprende liposomas con un compuesto inhibidor de la proteasoma con péptido de ácido borónico atrapado en los liposomas; más específicamente, los liposomas que tienen un compuesto de la Fórmula l ó II atrapados en el compartimento acuoso interior se cargan con un compuesto peptídico de ácido borónico, para formar un compuesto de éster boronato dentro del compartimento acuoso liposomal; en una modalidad, los liposomas tienen un recubrimiento externo de cadenas poliméricas hidrófilas y se utilizan para tratar un tumor sólido en un sujeto.
MX2010002101A 2007-08-21 2008-08-21 Formulaciones de liposomas de compuestos de acido boronico. MX2010002101A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95704907P 2007-08-21 2007-08-21
PCT/US2008/073844 WO2009026430A2 (en) 2007-08-21 2008-08-21 Liposome formulations of boronic acid compounds

Publications (1)

Publication Number Publication Date
MX2010002101A true MX2010002101A (es) 2010-03-26

Family

ID=39772869

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002101A MX2010002101A (es) 2007-08-21 2008-08-21 Formulaciones de liposomas de compuestos de acido boronico.

Country Status (16)

Country Link
US (1) US20090092662A1 (es)
EP (1) EP2190412A2 (es)
JP (1) JP2010536875A (es)
KR (1) KR20100066515A (es)
CN (1) CN101795672A (es)
AU (1) AU2008288920A1 (es)
BR (1) BRPI0815713A2 (es)
CA (1) CA2697044A1 (es)
CO (1) CO6260057A2 (es)
EA (1) EA201070297A1 (es)
EC (1) ECSP109983A (es)
MX (1) MX2010002101A (es)
NI (1) NI201000030A (es)
SV (1) SV2010003487A (es)
WO (1) WO2009026430A2 (es)
ZA (1) ZA201002011B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10125388B2 (en) * 2007-10-31 2018-11-13 Akonni Biosystems, Inc. Integrated sample processing system
WO2009155135A1 (en) * 2008-06-18 2009-12-23 Alza Corporation Composition comprising liposome-entrapped doxorubicin and methods of admnistration for treatment of multiple myeloma
US9034829B1 (en) * 2011-10-27 2015-05-19 Northwestern University pH-sensitive polymer-drug conjugates for targeted delivery of therapeutics
CN106132970B (zh) 2014-02-03 2020-09-04 俄亥俄州创新基金会 硼酸酯和其药物制剂
AU2016256979B2 (en) * 2015-05-04 2021-01-28 Versantis AG Method for preparing transmembrane pH-gradient vesicles
CN109045272A (zh) * 2018-08-01 2018-12-21 厦门市壳聚糖生物科技有限公司 一种硼替佐米磷脂复合物及其制备方法与应用
US20220387460A1 (en) * 2019-11-11 2022-12-08 Washington University Liposome compositions and methods of treatment targeted to tumor endothelium
WO2024035871A1 (en) * 2022-08-12 2024-02-15 Aviko Radiopharmaceuticals, Llc Small molecules for boron neutron capture therapy
US20240132524A1 (en) * 2022-09-21 2024-04-25 Aviko Radiopharmaceuticals, Llc Small molecules for boron neutron capture therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1396269A1 (en) * 2002-09-09 2004-03-10 Trigen Limited Boronic acid salts of multivalent metals used in the preparation of a medicament for treating thrombosis
EP1802278A4 (en) * 2004-10-22 2012-08-01 Dynamis Therapeutics Inc DERIVATIVE ADMINISTRATION OF N-METHYL-GLUCAMINE AND N-METHYL-GLUCAMINE COMPOUNDS
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds

Also Published As

Publication number Publication date
ECSP109983A (es) 2010-04-30
WO2009026430A2 (en) 2009-02-26
SV2010003487A (es) 2010-08-10
JP2010536875A (ja) 2010-12-02
CO6260057A2 (es) 2011-03-22
CA2697044A1 (en) 2009-02-26
AU2008288920A1 (en) 2009-02-26
NI201000030A (es) 2010-07-29
ZA201002011B (en) 2011-05-25
US20090092662A1 (en) 2009-04-09
BRPI0815713A2 (pt) 2015-02-10
EP2190412A2 (en) 2010-06-02
CN101795672A (zh) 2010-08-04
KR20100066515A (ko) 2010-06-17
WO2009026430A3 (en) 2009-11-26
EA201070297A1 (ru) 2010-08-30

Similar Documents

Publication Publication Date Title
MX2010002101A (es) Formulaciones de liposomas de compuestos de acido boronico.
TW200618820A (en) Liposome formulations of boronic acid compounds
WO2008072954A3 (en) Liposomes containing a polyphenol derivative such as caffeic acid and a method of post-loading thereof
MX2010002100A (es) Composiciones de liposomas para administracion in vivo de compuestos de acido boronico.
IN2014DN08886A (es)
PH12015501192A1 (en) Boronate ester compounds and pharmaceutical compositions thereof
TW200612966A (en) Boron-containing compounds and methods of use
WO2008137758A3 (en) Amino acid lipids and uses thereof
MX2011007536A (es) Compuestos beta amino ester y usos de los mismos.
WO2007115821A3 (en) Organic compounds
EA201270046A1 (ru) Новые производные фенилимидазола в качестве ингибиторов фермента pde10a
MX2014003844A (es) Materiales de fosforo y dispositivos relacionados.
WO2013085554A3 (en) Oxidative dyeing compositions comprising an 1-hexyl/heptyl-4,5-diaminopyrazole and a naphthalen-1-ol and derivatives thereof
AU2011325479A8 (en) 7-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyrazine derivatives
MX335945B (es) Composicion antifungica novedosa.
NZ593524A (en) A nonapeptide with anti-tumour activity
WO2010039654A3 (en) Topical treatment of skin infection
WO2010021934A3 (en) Azaindole inhibitors of iap
WO2012091408A3 (en) Matrix type antimicrobial vehicle and manufacturing method thereof
WO2009114470A3 (en) Tetrahydroindole and tetrahdyroindazole as hsp90 inhibitors containing a zinc binding moiety
WO2008008155A3 (en) Small molecule modulators of p53 family signaling
TW200716653A (en) Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases
TW200716577A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases
WO2011130317A3 (en) Therapeutic agents having reduced toxicity
WO2008134289A3 (en) High relaxivity coordinatively unsaturated lanthanide complexes

Legal Events

Date Code Title Description
FA Abandonment or withdrawal